Atibuclimab is under clinical development by Implicit Bioscience and currently in Phase I for Parkinson’s Disease. According to GlobalData, Phase I drugs for Parkinson’s Disease have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Atibuclimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Atibuclimab overview
IC-14 is under development for the treatment of ST-elevation myocardial infarction, arrhythmogenic cardiomyopathy, Parkinson's disease, retinal diseases, acute decompensated heart failure (ADHF), skeletal diseases, neurotrauma, rare diseases. It is a recombinant chimeric monoclonal antibody. It acts by targeting CD14, an essential component of the innate inflammatory response to bacterial infection. The drug candidate is administered through intravenous route. It was under development for the treatment of acute lung injury, community-acquired pneumonia, dengue fever, Coronavirus disease 2019 (COVID-19), motor neurone disease (amyotrophic lateral sclerosis or ALS), and sepsis toxic shock.
Implicit Bioscience overview
Implicit Bioscience is a biotechnology company that develops drugs in the field of immunoneurology and therapies for life-threatening diseases. Implicit Bioscience is headquartered in Woolloongabba, Queensland, Australia.
For a complete picture of Atibuclimab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
